瑞舒伐他汀联合普罗布考对老老年不稳定心绞痛患者的有效性及安全性评价  

Study on Effect and Safety of Rosuvastatin Combined with Probucol in Treatment of Elder Patients with ACS

作　　者：范瑞云[1] 杨静茹[2] 周斌[2] 

机构地区：[1]中国人民解放军第272医院急诊急救中心,天津和平区300020 [2]中国人民解放军第266医院,河北承德067000

出　　处：《河北医学》2015年第10期1645-1648,共4页Hebei Medicine

摘　　要：目的：观察瑞舒伐他汀联合普罗布考对老老年不稳定心绞痛（UA）患者的有效性及安全性。方法：78例80岁以上UA患者随机分到他汀组瑞舒伐他汀5-10mg/d,n=39）与联合治疗组（瑞舒伐他汀5-10mg/d和普罗布考500mg/d,n=39）。治疗前、1周、4周、2个月及半年后分别测血清血脂、血糖、肝肾功能及肌酸激酶,并应用高频超声测肱动脉血流介导的内皮依赖血管舒张功能（FMD）和由硝酸甘油诱导的内皮非依赖血管舒张功能（NMD）。结果：两组血清总胆固醇、低密度脂蛋白胆固醇（LDL-C）明显低于治疗前。Objective： To evaluate the study on effect and safety of rosuvastatin combined with probucol in treatment of elder patients with acute coronary syndrome（ ACS）. Methods： 78 patients,aged 80 years,with ACS were randomized to receive rosuvastatin（ 10 mg / d） and probucol（ 500 mg / d,combination group,n= 39） or rosuvastatin（ 10 mg / d） alone（ rosuvastatin group）. Endothelium dependent flow mediated dilatation（ FMD） and endothelium-independent sublingual nitroglycerin-mediated dilatation（ NMD） as well as the levels of lipids,glucose,liver and renal funtion,and creatine kinase（ CK） were assessed at baseline,1 week,4weeks,2 mouths and a half of year after therapy. Result： Compared to baseline,the levels of total cholester and LDL-C were significantly reduced in both groups.FMD equally increased after l week in both groups（ rosuvastatin group： 3.79% ±0.79% vs. 1.10% ±0.44%,combination group： 3.80% ±0.38% vs.1.04% ± 0.37%;P〈0.01）.Post a half of year therapy,FMD increase was significantly higher in combination group than that in rosuvastatin group（ 7.01% ±0.73 6%%vs.5.10% ±0.91% P〈0.0.05）. Liver and renal function,glucose,and CK had no significant change. Conclusion： The combined rosuvastatin and probucol in treatment of elder patient with ACS is significantly effective and comparatively safe; The combined rosuvastatin and probucol is superior to rosuvastatin alone on improving endothelial function.

关 键 词：老年 冠状动脉疾病 内皮血管 降血脂药 

分 类 号：R541.4[医药卫生—心血管疾病]